Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - Mar 27, 2025 - "UPCOMING EXPECTED EVENTS AND MILESTONES:...(i) Complete enrollment of Cohort 1 in the ReSPECT-LM Phase 1 multiple dose administration trial in 2025; (ii) Complete end of Phase 1 meeting with the U.S. FDA for the ReSPECT-LM trial and determine next clinical steps in 2025; (iii) Complete ReSPECT-GBM Phase 2 enrollment in 2025; (iv) Obtain IND approval for the ReSPECT-PBC Phase 1/2 trial of REYOBIQ for pediatric ependymoma and high-grade glioma in H2 2025."
Enrollment status • FDA event • IND • Ependymoma • Glioblastoma • Glioma
|